Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
IgA nephropathy (IgAN) is the most prevalent primary glomerulonephritis globally and a leading cause of end-stage renal disease. While IgA1 has been recognized as the primary pathogenic subclass in IgAN, the role of IgA2 has remained controversial and less explored due to methodological limitations in past studies. This study was designed to comprehensively investigate the potential involvement of IgA2 in the pathogenesis of IgAN and its clinical implications.
To characterize glomerular IgA2 deposition in IgAN, we performed laser capture microdissection coupled with mass spectrometry (LCM/MS) on renal biopsies from 14 IgAN patients and 10 healthy donors. Additionally, multicenter immunofluorescence analysis was conducted using validated subclass-specific antibodies on 161 biopsy-proven IgAN cases from three Chinese clinical centers (PK, XA, SC). To establish IgA2's independent pathogenicity, we generated humanized IgA1/IgA2 mouse models and induced IgAN via intraperitoneal administration of Lactobacillus casei cell wall extract (LCWE) with complete Freund's adjuvant (CFA).
Through LCM/MS analysis, we detected both IgA2(m1) and IgA2(m2) subtypes in the glomerular mesangium of IgAN patients (Figure A), although their levels were significantly lower than those of IgA1. Quantification of relative peptide abundance clearly showed elevated levels of IgA subclasses in IgAN patients compared to donors. Multicenter immunofluorescence staining across the three Chinese cohorts demonstrated consistent mesangial deposition of IgA2 in over 98% of the cases (Figure B). Moreover, the intensity of IgA2 deposition was significantly correlated with chronic histological damage (such as Oxford classification M/S/T lesions) and a decline in estimated glomerular filtration rate (eGFR). In the humanized IgA2 mice treated with LCWE exhibited IgA2 mesangial deposition and developed characteristic tubular atrophy, which was not observed in the humanized IgA1 mice (Figure C). Additionally, humanized IgA2 mice showed stronger glomerular C3 activation and interstitial macrophage infiltration compared to humanized IgA2 mice.
This study provides strong evidence the role of IgA2 in the development of IgAN, demonstrating its capacity for glomerular deposition, complement activation, and induction of distinct histopathological injury patterns. These findings necessitate the incorporation of IgA2-specific targeting in future therapeutic strategies for IgAN.
